Trial 0C-21-14


A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Negeen Izadian, Coordinator, Cristina Lee, Coordinator, Diane Habib, Coordinator, Clara Karam, D.M., Judy Smith, Coordinator, Stephanie Kim, Coordinator, Maura Fernandez, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.